Hello, everyone, and how are you this morning? We are doing just fine, thank you. And why not? The Pharmalot campus is blessed with a warm and shiny sun, a clear blue sky, and a deliciously cool breeze. Not to mention a functioning coffee kettle for brewing hot cups of stimulation. Of course, while we enjoy these gifts, we are also foraging for items of interest, some of which you can find below. We hope these help you on your journey today and you conquer the world. Meanwhile, please do stay in touch …

Louisiana and Gilead Sciences (GILD) are working on a deal to change how the state pays for hepatitis C drugs, NPR tells us. The idea is a subscription, or the Netflix (NFLX) model — the state would agree to pay a fixed amount of money over several years and, in turn, the drug maker would provide all the medication that is needed. Initially, Louisiana would get more drug than it would pay for, but in later years, Gilead would get extra money. “Ideally, we would have something in place this year,” says Gregg Alton, executive vice president of corporate and medical affairs at Gilead.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy